- Sanofi gains exclusive license to Innate’s B7H3 ANKETTM
program and options for two additional targets; Upon candidate
selection, Sanofi will be responsible for all development,
manufacturing and commercialization
- Innate to receive €25m upfront and up to €1.35bn in total
milestones plus royalties from Sanofi
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi
(NASDAQ: SNY) announced today an expansion of their collaboration,
with Sanofi licensing a natural killer (NK) cell engager program
targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell
Engager Therapeutics) platform. Sanofi will also have the option to
add up to two additional ANKETTM targets. Upon candidate selection,
Sanofi will be responsible for all development, manufacturing and
commercialization.
Innate and Sanofi signed a first NK cell engagers collaboration
in 2016 for the generation and evaluation of up to two bispecific
NK cell engagers, which are currently being evaluated by Sanofi’s
R&D team, with one of these molecules already in clinical
studies.
Valeria Fantin, Ph.D., Global Head of Oncology Research at
Sanofi
“At Sanofi, we are exploring the potential of NK cells for
cancer immunotherapy, a key pillar for our oncology strategy. Our
relationship with Innate aligns with our commitment to work with
promising French companies and supports our ambition to develop a
diverse portfolio of next-generation NK cell engagers, highly
synergistic with Sanofi’s allogeneic NK cell platform, engineered
lymphokines that stimulate NK cells, and growing Immuno-oncology
pipeline. As a leading global company with roots in France, we are
proud to collaborate to support the French healthcare
ecosystem.”
Yannis Morel, Ph.D., Executive Vice President, Product
portfolio strategy & Business development at Innate
Pharma
“Building on the success of our existing collaboration on
hematologic targets, we are pleased to expand and strengthen our
partnership with Sanofi on NK Cell Engagers with the addition of up
to three new programs, including in solid tumors. Sanofi’s
investment in Innate further validates the value of our ANKETTM
platform and its potential to address multiple tumor types. By
incorporating various tumor antigen binders, NK Cell Engagers are a
versatile technology that may provide new options for patients and
offer clinical benefit across multiple cancers, whilst also
maintaining a good safety profile. This agreement also highlights
Innate’s strategy to build a broad portfolio of ANKET programs
addressing different types of cancer.”
Under the terms of the new license agreement, Innate will
receive €25m upfront payment and up to €1.35bn total in
preclinical, clinical, regulatory and commercial milestones plus
royalties on potential net sales. Closing of the transaction is
subject to HSR approval.
About ANKETTM
ANKETTM (Antibody-based NK cell Engager Therapeutics) is
Innate's proprietary platform for developing next-generation,
multi-specific natural killer (NK) cell engagers to treat certain
types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer. It leverages the advantages of harnessing NK cell
effector functions against cancer cells and also provides
proliferation and activation signals targeted to NK cells.
Our latest innovation, the tetra-specific ANKET molecule, is the
first NK cell engager technology to engage activating receptors
(NKp46 and CD16), a tumor antigen and an interleukin-2 receptor
(via an IL-2 variant, IL-2v) via a single molecule.
About 2016 Sanofi/Innate research collaboration and licensing
agreement
In 2016, Sanofi and Innate entered into a research collaboration
and licensing agreement for the generation and evaluation of up to
two bispecific NK cell engagers, using technology from Innate
Pharma and Sanofi’s proprietary bispecific antibody format as well
as tumor targets.
A Phase 1/2 clinical trial by Sanofi is ongoing, evaluating
IPH6101/SAR’579 (SAR443579), the first NKp46/CD16-based
CD123-targeted ANKETTM NK cell engager, in patients with relapsed
or refractory acute myeloid leukemia (R/R AML), B-cell acute
lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic
syndrome (HR-MDS).
In the summer 2022, Sanofi had made the decision to progress
IPH6401/SAR’514 (SAR445514) into investigational new drug
(IND)-enabling studies. IPH6401/SAR’514 is a BCMA-targeting NK cell
engager using Sanofi’s proprietary CROSSODILE® multi-functional
platform, which comprises the Cross-Over-Dual-Variable-Domain
(CODV) format. It induces a dual targeting of the NK activating
receptors, NKp46 and CD16, for an optimized NK cell activation,
based on Innate’s ANKETTM proprietary platform.
Under the terms of the original license agreement, Sanofi is
responsible for the development, manufacturing and
commercialization of products resulting from the research
collaboration. Innate Pharma will be eligible to up to €400m in
development and commercial milestone payments as well as royalties
on net sales. To date, €13m milestone payments to Innate have been
announced.
About Sanofi’s approach to NK therapies in oncology
At Sanofi, we are exploring the intrinsic abilities of Natural
Killer cells to create new immunotherapies for patients with
cancer. Natural Killer cell-based therapies are a key pillar within
Sanofi’s Oncology strategy. By activating the innate power of NK
cells, Sanofi is advancing a diverse and complementary range of
NK-based therapeutics to transform immune biology. The breadth of
our modalities and unique strength to innovate end-to-end maximizes
the therapeutic possibilities for more people with cancer.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across some 100 countries, is dedicated to
transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2021, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221218005037/en/
Innate Pharma Media Relations Arthur
Rouillé | +33 1 44 71 00 15 | innate@newcap.eu
Investors Relations Henry Wheeler | +33 (0)4 84 90
32 88 | henry.wheeler@innate-pharma.fr
Sanofi Media Relations Sandrine Guendoul |
+ 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Sally Bain
| + 1 617 834 6026 | sally.bain@sanofi.com Kate Conway | + 1
508 364 4931 | kate.conway@sanofi.com
Investor Relations Eva Schaefer-Jansen | + 33 7 86
80 56 39 | eva.schaefer-jansen@sanofi.com Arnaud Delépine |
+ 33 6 73 69 36 93 | arnaud.delepine@sanofi.com Corentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.com Felix Lauscher | + 1 908 612
7239 | felix.lauscher@sanofi.com Priya Nanduri | +1 617 764
6418 | priya.nanduri@sanofi.com Nathalie Pham | + 33 7 85 93
30 17 | nathalie.pham@sanofi.com
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mär 2023 bis Mär 2024